Pfizer’s Commitment to Global Public Health

Fundamental to Pfizer’s approach in supporting global public health is the understanding that our business and societal mission is the same: we discover, develop and bring to market life-saving medicines and vaccines that improve people’s lives while helping to ensure that individuals have access to these medicines. In partnership with NGOs, private and public foundations, Pfizer applies its full resources – our people, medicines and vaccines, and funding – to improve global public health. In addition to traditional philanthropic approaches, we support new, collaborative and market-based strategies and cultivate innovation on a local level to address pressing healthcare challenges for the most vulnerable around the world.

Background
For more than 160 years, Pfizer has been making significant and far-reaching global health contributions, reaching millions of individuals every year. Historically, to achieve global health goals, Pfizer used traditional philanthropic approaches: large-scale cash and product donations. However, against a backdrop of a dramatically changing world, we believe that private sector companies like Pfizer have to think and act differently about global health challenges that affect the most vulnerable.

All over the world significant societal and economic shifts are continually challenging the ways in which we think about global public health. Current social issues include governments’ growing burden to unilaterally address their populations’ health needs, the additional strains on health systems caused by shifting demographics and migration, income inequality and health inequity.

To help advance global public health in this changing environment, Pfizer works with a variety of partners – from international non-governmental organizations (NGOs), to governments, to community health workers – to create catalytic ways to create lasting global health solutions that are specific to the needs of the communities and people we serve.

Pfizer’s Position
At Pfizer, we apply our full resources – our people, products, and funding – to improve global public health by supporting new, collaborative and market-based strategies, evolving traditional philanthropic approaches, and cultivating innovation on a local level to address healthcare challenges. Specifically, our programs highlight how our innovative approach is enabling us to address global health challenges in a dynamic and responsive way.

We work to ensure that our global public health efforts are innovative, measurable and sustainable. Specifically our programs affecting global public health:

- **Address immediate health needs** through product donations and humanitarian programs, leveraging new technologies like disease mapping, when appropriate, to better reach patients in need.
- **Evolve legacy philanthropy programs** to better address patient needs – regardless of a country’s development status.
- **Utilize new and creative commercial strategies** to broaden access to our medicines and vaccines in emerging markets.
- **Catalyze local innovation** through programs and partnerships that aim to strengthen healthcare systems and sustainably address complex health challenges.

Working within the United Nations Sustainable Development Goals (SDGs) framework, our approaches and programs seek to advance the goals in close collaboration with NGOs and governments. Our work together addresses many SDG targets, including ensuring health and well-being.
Key Facts and Figures

- We have 14 global programs and commercial transactions designed to increase access to medicines in emerging markets, including the International Trachoma Initiative and participation in the GAVI Alliance Advance Market Commitment (AMC) for pneumococcal vaccines.

- In the US, in the last five years (2013-2017, Pfizer helped nearly 1.2 million patients in need get access to over 13.8 million Pfizer prescriptions for free or at a savings.

- Through Pfizer’s commitment to skills-based volunteering, colleagues have completed 385+ catalytic projects worldwide, addressing pressing global health issues and furthering progress toward the United Nations Sustainable Development Goals. 490+ colleagues have contributed their expertise and time in nearly 50 countries to work with 73 partner organizations around the world. Together, our colleagues have contributed approximately 370,000 hours of service.

- Through one of Pfizer’s signature product donation programs, the International Trachoma Initiative (ITI), Pfizer has donated more than 717 million antibiotic doses of it antibiotic to treat and prevent blinding trachoma.

- Pfizer has partnered with Gavi, the Vaccine Alliance, through the Advance Market Commitment (AMC), to supply 930 million doses of our pneumococcal conjugate vaccine through 2027 at a non-commercial price to the world’s poorest countries.

- As part of our longstanding support for humanitarian emergency relief around the world, Pfizer established a new tier for its multi-dose vial presentation of pneumococcal conjugate where it is provided at the lowest global price for civil society organizations (CSOs) working in emergency settings, as designated by WHO. To date, we have signed agreements with several CSO partners under this humanitarian emergency tier, resulting in the delivery of hundreds of thousands of doses our pneumococcal conjugate vaccine in Africa and the Middle East to vaccinate those in unfortunate humanitarian emergency settings.

- Through a collaboration with the Bill & Melinda Gates Foundation, and The Children’s Investment Fund Foundation, more than 16 million units of Pfizer’s all-in-one injectable contraceptive Sayana® Press (medroxyprogesterone acetate) had been shipped to 23 countries in the developing world by the end of 2017, potentially reaching more than 4 million women.

Examples of Pfizer’s Global Public Health Programming

The initiatives below illustrate how Pfizer helps to improve access to healthcare and medicines around the world.

- **International Trachoma Initiative** – Since 1998, Pfizer has worked to combat blinding trachoma, partnering with organizations including the World Health Organization’s Alliance for the Global Elimination of Blinding Trachoma by 2020 (GET2020) and the International Trachoma Initiative. Trachoma is an infectious eye disease that after repeated infections may cause eyelids to turn in and lashes to scrape the eyeball, causing great pain, corneal ulcers and irreversible blindness. It is the world’s leading infectious cause of blindness and affects the poorest of the poor, with nearly 182 million people living in trachoma-endemic areas in 42 countries.

  Relatedly, Pfizer recently participated in a study led by the University of California San Francisco and funded by the Bill & Melinda Gates Foundation to evaluate the impact on overall child mortality of a single dose of Zithromax given twice annually to children under the age of five in Niger, Malawi and Tanzania. Results published in April 2018 in the *New England Journal of Medicine* showed that a single dose reduced the overall number of child deaths by 13.5%. Additional studies are needed to further understand the antibiotic’s potential role in reducing child mortality around the world. For now, Pfizer is committed to donating Zithromax and placebo for future studies, and will continue working with academic investigators, partner organizations and other stakeholders to determine the best path forward as it pertains to the study results and public health impact.

- **Vaccines Partnership in Emerging Markets** – In 48 of the world’s poorest countries, Pfizer partners with Gavi, the Vaccine Alliance to sell our pneumococcal conjugate vaccine at the lowest
global price. To date, Pfizer has provided more than 340 million doses, helping to protect 29 million babies in Gavi countries each year. In 2017, Pfizer extended our Gavi partnership to include five provinces in India, protecting an additional 5 million babies annually. One out of every two doses of our pneumococcal conjugate vaccine that Pfizer distributes goes to the world’s poorest countries through our partnership with Gavi, the Vaccine Alliance.

The Pfizer Foundation – Grants and investments provided through the Foundation seek to: (1) catalyze and scale high impact innovations that have the potential to improve health for underserved populations in low- and middle-income countries; (2) address barriers to health care for women and children by supporting innovative programs that integrate the delivery of immunizations and family planning services and (3) encourage innovative thinking and advances which help promote care for non-communicable diseases (NCDs), which include cardiovascular disease, diabetes and mental health.

Transforming Access to Contraception – Pfizer supports the Family Planning 2020 global partnership to expand access to voluntary family planning to 120 million additional women by 2020. We took our heritage injectable contraceptive product and worked to redesign it to meet the needs of women living in the identified priority countries. The result, Sayana® Press (medroxyprogesterone acetate), is a subcutaneous contraceptive in a prefilled, single-use, Uniject® delivery system that eliminates the need to prepare a needle and syringe, and allows it to be administered outside a clinical setting, with the potential for self-injection if locally-approved.

Collaborations to Increase Access to Lifesaving Cancer Treatment in Africa – Pfizer is collaborating with the American Cancer Society and the Clinton Health Access Initiative to provide access to critical cancer treatments such as chemotherapies in Ethiopia, Nigeria, Tanzania, Kenya, Uganda and Rwanda. Under the agreement, Pfizer will offer affordable access to eleven high-quality cancer treatments through government tenders and procurement mechanisms. Nine of the eleven medicines are on the WHO Essential Medicine List (EML) and are part of the treatment regimens for some of the most common cancers in sub-Saharan Africa including breast, cervical and colorectal cancer.

Healthy Communities – In 2017, Pfizer initiated a collaboration with the international, non-profit organization Population Services International. This $1 million collaboration will improve the diagnosis and treatment of hypertension, a condition that can often lead to stroke and impacts one-quarter of all adults in Myanmar and Vietnam, as a leading cause of mortality. The Healthy Communities program seeks to develop sustainable and scalable models of hypertension management to underserved communities and aims to train 400 health care providers in 360 private sector health facilities and targets screening up to 500,000 people in these countries.

Pfizer RxPathways — For more than 30 years, Pfizer has helped U.S. patients in need get access to their Pfizer medicines. Today, through Pfizer RxPathways, we help connect patients who are struggling to afford their Pfizer prescription medicines to a range of assistance programs. Pfizer RxPathways connects eligible patients to a full range of Pfizer assistance programs that enable them to access insurance support, co-pay help, and medicines for free or at a savings.

Pfizer Global Health Fellows & Global Health Teams (GHF/GHT) — For 15 years, Pfizer has pioneered a collaborative approach to deliver on their commitment to address pressing health needs in underserved communities around the world through its skills-based volunteering initiatives, Global Health Fellows & Global Health Teams. GHF/GHT, is an international corporate volunteer program, places Pfizer colleagues and teams in three- to six-month assignments with leading international development organizations. On assignments, fellows transfer their professional expertise to strengthen access, quality, and efficiency of health services in under-resourced communities.

---

1 Where each woman is assumed to have used 4 doses of the total number shipped (2014-2017).
3 The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.